港股異動 | 澳優(1717.HK)續跌逾5% Q2增長輕微放緩 績後遭花旗降目標價
格隆匯8月3日丨上週五(7月31日)午後跳水並最終收跌10.24%的澳優(1717.HK)今日續跌,現報12.28港元,跌5.39%,暫成交1.3億港元,最新總市值198億港元。澳優上週五午間發公告稱,預計2020年中期經調整公司權益持有人應占利潤同比增加30.1%至34.7%。不過,集團收入於今年第二季度的增長較第一季度輕微放緩。於今年5月下旬,若干品牌在分銷方面出現庫存過剩。花旗最新發研報指,將公司2020、2021及2022年的盈利預測分別下調6%、 8%及 8%,以反映其銷售情況受到負面影響。該行將澳優目標價由22.4港元下調至18.9港元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.